Bristol-Myers Squibb BMY
Bristol-Myers Squibb is a global pharmaceutical company that develops and commercializes innovative medicines in areas such as oncology, immunology, and cardiovascular diseases. Bristol-Myers Squibb shows solid fundamentals with a 46.6% ROE, 34.4% operating margin, and a 13.85 P/E, but the 153% earnings growth is unsustainable and the regulatory pause in CAR-T adds uncertainty.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Bristol-Myers Squibb is a global pharmaceutical company that develops and commercializes innovative medicines in areas such as oncology, immunology, and cardiovascular diseases. Bristol-Myers Squibb shows solid fundamentals with a 46.6% ROE, 34.4% operating margin, and a 13.85 P/E, but the 153% earnings growth is unsustainable and the regulatory pause in CAR-T adds uncertainty.
Score by category
| Category | Score |
|---|---|
| Financial health | 7.5 |
| Quality / Moat | 8.3 |
| Valuation | 6.4 |
| Growth | 7.6 |
| Dividend | 8.1 |
| Momentum | 8.9 |
| Risk & Context | 8.7 |
OVERALL SCORE: 7.8/10
Context and risks
Regulatory pause in autoimmune CAR-T studies (Breyanzi) adds uncertainty to the timeline of a key growth program. The prolonged high-rate environment pressures the multiple of a dividend stock, though moderate debt (ND/EBITDA 1.8) limits the impact.
News considered in the analysis
- Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? — Artículo comparativo sin información nueva sobre BMY; es ruido.
- Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review — Noticia sobre Xenon, no sobre BMY; sin impacto directo.
- Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. — Tipos altos prolongados presionan la valoración de los dividendos, pero es un factor macro ya ampliamente descontado en el sector.
- Novartis (NVS) and Bristol Myers (BMY) Pause Autoimmune CAR-T Studies. Can Their Programs Recover? — Pausa regulatoria en estudios CAR-T autoinmunes; retrasa un programa clave pero no es un fracaso definitivo.
- Pfizer Stock Paid Out $49B: So Why Did Investors Lose Money? — Noticia sobre Pfizer, no sobre BMY; sin impacto directo.
Verdict: Hold; the attractive valuation and 4% dividend provide support, but regulatory uncertainty and unsustainable growth limit upside potential.
Main risk: The regulatory pause in autoimmune CAR-T studies could delay a key growth program and affect market confidence in the product pipeline.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →